Genmab A/S
HealthcareNASDAQ:GMAB · NASDAQ Global Select
-$0.20 today
Vol 0.80M · Avg 1.80M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.9B of revenue converted into $821.0M of net income for the selected period. Gross margin is 93.3% and net margin is 21.1%, showing how much revenue survives after costs and taxes. EPS is $1.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B -82.7% | $21.5B +30.7% | $16.5B +13.6% | $14.5B +72.3% | $8.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $309.2M -68.6% | $985.0M +335.8% | $226.0M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.4B -83.4% | $20.5B +26.4% | $16.2B +12.0% | $14.5B +72.3% | $8.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 91.7% -3.7pp | 95.4% -3.2pp | 98.6% -1.4pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.6B -84.0% | $9.7B +27.8% | $7.6B +37.2% | $5.6B +33.0% | $4.2B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $602.5M -84.1% | $3.8B +15.0% | $3.3B +23.2% | $2.7B +108.6% | $1.3B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.2B -84.4% | $13.8B +26.6% | $10.9B +32.6% | $8.2B +50.8% | $5.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $71.1M -82.8% | $413.0M +72.1% | $240.0M -33.7% | $362.0M +44.8% | $250.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.3B -86.2% | $9.7B +63.1% | $5.9B -19.0% | $7.3B +75.7% | $4.2B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 35.9% -9.1pp | 45.0% +8.9pp | 36.1% -14.5pp | 50.6% +1.0pp | 49.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.3B -81.3% | $6.7B +26.0% | $5.3B -15.1% | $6.3B +112.2% | $3.0B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 33.6% +2.5pp | 31.1% -1.2pp | 32.3% -10.9pp | 43.2% +8.1pp | 35.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $138.1M -86.1% | $995.0M +6.0% | $939.0M +189.8% | $324.0M +64.5% | $197.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $61.0M -49.1% | $120.0M +344.4% | $27.0M +28.6% | $21.0M +61.5% | $13.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$46.0M -101.9% | $2.5B +678.8% | $316.0M -53.4% | $678.0M -29.7% | $965.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.2B -86.9% | $9.2B +62.6% | $5.6B -18.8% | $6.9B +77.3% | $3.9B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.4% -10.2pp | 42.6% +8.4pp | 34.2% -13.7pp | 47.9% +1.3pp | 46.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $241.2M -81.7% | $1.3B +2.7% | $1.3B -13.9% | $1.5B +55.4% | $961.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $963.8M -87.7% | $7.8B +80.2% | $4.4B -20.2% | $5.5B +84.4% | $3.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 25.9% -10.6pp | 36.4% +10.0pp | 26.4% -11.2pp | 37.6% +2.5pp | 35.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -87.2% | $12 +83.9% | $7 -20.9% | $8 +84.5% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -87.3% | $12 +83.9% | $7 -20.1% | $8 +84.4% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $621.5M -3.8% | $646.3M -1.9% | $659.2M +0.8% | $653.9M -0.0% | $654.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $626.9M -3.0% | $646.3M -1.9% | $659.1M -0.1% | $660.1M -0.1% | $660.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.53B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
United Therapeutics Corporation
NASDAQ:UTHR
$23.02B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.82B
Incyte Corporation
NASDAQ:INCY
$21.77B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.14B
Tenet Healthcare Corporation
NYSE:THC
$15.20B
Exelixis, Inc.
NASDAQ:EXEL
$13.38B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.76B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GMAB generate?
Genmab A/S (GMAB) reported $3.72B of revenue in fiscal 2025.
Is GMAB profitable?
Genmab A/S (GMAB) reported $963.76M of net income, with a net margin of 25.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.